The cost burden of multiple sclerosis in the United States: a systematic review of the literature

References

• Dutta R, Trapp B. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68(22 Suppl 3):S22-31
   PubMed Web of Science ®Google Scholar
• Kasper LH, Shoemaker J. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 2010;74(Suppl 1):S2-8
   Web of Science ®Google Scholar
• Disanto G. The evidence for a role of B cells in multiple sclerosis. Neurology 2012;78:823-32
   PubMed Web of Science ®Google Scholar
• Multiple sclerosis. PubMed Health. US National Library of Medicine, 2011. www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed July 31, 2012
   Google Scholar
• The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• PRISMS. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001;56:1628-36. Erratum in Neurology 2001;57:1146
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8
   PubMed Web of Science ®Google Scholar
• Polman C, O’Connor RW, Havrdova E, et al. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Phillips AL, Bergman RE, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis. J Med Econ 2012;15:601-9
   PubMedGoogle Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al; PreCISe Study Group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Curkendall SM, Wang C, Johnson BH, et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease modifying therapy. Clin Ther 2011;14:61-9
   Google Scholar
• Brook RA, Rajagopalan K, Kleinman NL, et al. Absenteeism and health-benefit costs among employees with MS. Curr Med Res Opin 2009;25:1469-76
   PubMed Web of Science ®Google Scholar
• Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based evaluation. Neurology 2011;77:355-63
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Brook RA, Beren IA, et al. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Curr Med Res Opin 2011;27:179-88
   PubMed Web of Science ®Google Scholar
• Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ 2010;13:464-71
   PubMedGoogle Scholar
• Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther 2009;26:552-62
   PubMed Web of Science ®Google Scholar
• Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 2009;27:681-91
   PubMed Web of Science ®Google Scholar
• Oleen-Burkey M, Castelli-Haley J, Lage MJ, et al. Burden of a multiple sclerosis relapse. Patient 2012;5:57-69
   PubMedGoogle Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin 2009;25:869-77
   PubMed Web of Science ®Google Scholar
• Gilden DM, Kubisiak J, Zbrozek AS. The economic burden of Medicare-eligible patients by multiple sclerosis type. Value Health 2011;14:61-9
   PubMed Web of Science ®Google Scholar
• Lad SP, Chapman CH, Vaninetti M, et al. Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology 2010;35:93-9
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Center for Healthcare Research and Transformation. Health care cost drivers: chronic disease, comorbidity, and health risk factors in the U.S. and Michigan. Issue Brief July 2010. Center for Healthcare Research & Transformation. Ann Arbor, MI. http://www.chrt.org/publications/price-of-care/issue-brief-2010-08-health-care-cost-drivers/. Accessed November 14, 2012
   Google Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis; A systematic review of the literature. Pharmacoeconomics 2010;28:363-79
   PubMed Web of Science ®Google Scholar
• Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs 2010;70:1677-91
   PubMed Web of Science ®Google Scholar
• Wundes A, Brown T, Bienen EJ, et al. Contribution of intangible costs to the economic burden of multiple sclerosis. J Med Econ 2010;13:626-32
   PubMedGoogle Scholar
• Reese JP, John A, Wienemann G, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol 2011;66:311-21
   PubMed Web of Science ®Google Scholar
• Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Multi Scler 2005;11:232-9
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Graham J, Castelli-Haley J, et al. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy 2009;7:91-108
   PubMedGoogle Scholar
• Oleen-Burkey M, Kobelt G, Borgstrom F. Costs and quality of life of patients with relapsing-remitting multiple sclerosis currently on immunomodulatory therapy in the United States. International Committee on Databases in Multiple Sclerosis, 2003; Abstract Hackensack, NJ
   Google Scholar
• Kobelt G, Bery J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56
   PubMed Web of Science ®Google Scholar
• Von Schaper E, Kresge N. Novartis’s $48,000 pill spurs U.S. price increases for older MS treatments. 2011. www.bloomberg.com/news/2011-03-21/novartis-s-48-000-pill-spurs-u-s-price-increases-for-ms-drugs.html. Accessed July 23, 2012
   Google Scholar
• Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol 2012;25(1 Suppl):S11-19
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves new multiple sclerosis treatment Aubagio. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm. Accessed November 2, 2012
   Google Scholar